# Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer

> **NCT02181556** · PHASE2 · COMPLETED · sponsor: **Federation Francophone de Cancerologie Digestive** · enrollment: 41 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** FOLFIRI Protocol
- **DRUG:** Aflibercept Injection

## Key facts

- **NCT ID:** NCT02181556
- **Lead sponsor:** Federation Francophone de Cancerologie Digestive
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2017-02
- **Final completion:** 2017-07
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2021-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02181556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02181556, "Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02181556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*